

**From Science to System:
Updating the FASD Forensic Assessment Protocol
for Justice, Clarity, and Change**

**Karen Steele, Moderator
Natalie Novick Brown, PhD
Paul D. Connor, PhD
Richard S. Adler, MD**

**FASD United 10th International Conference
Seattle, WA
April 19, 2026**

March 2026 Editor's Choice

An Updated FASD Assessment Protocol for the Forensic Context

Natalie Novick Brown

Paul D. Connor

Richard S. Adler






FORENSIC OBJECTIVITY

through:

- ✓ **Multidisciplinary Team (MDT)**
- ✓ **Independence**
- ✓ **Convergence**
- ✓ **Differential Diagnosis (DD)**
- ✓ **Continuous Quality Improvement (CQI)**

MDT: Independence and Convergence



Differential Diagnosis

Focus

1. PAE
2. Thinking & Behavior
3. Nexus

Continuous Quality Improvement (CQI) Grounded in the Evolving Science

- ✓ **Biopsychosocial Perspective**
- ✓ **Developmental Scope ('whole cloth')**
- ✓ **Relevant Empirical Research**
- ✓ **Neuroimaging**
- ✓ **Diagnostic Changes**



DIAGNOSTIC AND STATISTICAL
MANUAL OF
MENTAL DISORDERS

FIFTH EDITION

DSM-5™




AMERICAN PSYCHIATRIC ASSOCIATION

Context: Paradigm Shift


- ✓ **DSM-5 Diagnosis: ND-PAE & ID**
- ✓ **EF Emphasis**
- ✓ **ID-Equivalence**
- ✓ **Severity Determination**
- ✓ **Arrested Development**
- ✓ **‘General Acceptance’**

Whole-Cloth Perspective



ND-PAE (FASD) = a direct cause-and-effect disorder.


Severity



FASD Developmental Trajectory: Severity

[1996 Secondary Disabilities Study]

Brain Damage
+
ACEs
=
“Secondary
Disabilities”
(developmental
outcomes)



* Note that **FAE** (now, **ARND**) has worse outcomes than **FAS** in all but one area



“FAE” (Fetal Alcohol Effects) = ARND*

Protective factors:


- **Diagnosis before age 6**
- **FASD-informed services and supports**
- **Stable, nurturing home environment**
- **No violence exposure.**



Expected Cognitive Profiles

- **Variable performance**
- **Context-dependent functioning**
- **Arrested development**

Average Neuropsychological Profile of 131 Defendants Diagnosed with an FASD



The Developmental Paradox

Brain injury in utero is static, but the functional manifestation changes across the lifespan due to *minimal brain maturation as contextual demands increase*.

Arrested Development in Children

| Study | Age | Sample | Vineland Results |
|------------------------|-----------|---------------------------------------|--|
| Thomas et al., 1998 | 5-12y | FAS vs VIQ-matched vs normal controls | FAS lowest on all social skills (NC > VIQ > FAS); most impaired in interpersonal relationships; arrested development in FAS |
| Whaley et al., 2001 | 6-17y | PAE vs clinic controls | PAE showed greater age-related decline in socialization scores |
| Coles et al., 2009 | 6-17y | Heavy PAE vs ADHD vs controls | Mean composite at age 17 = 7y (Socialization = 6y) |
| Rasmussen et al., 2012 | 8-20y | FASD vs IQ-matched SLD vs controls | FASD = significantly lower in all adaptive domains vs both groups; arrested development in Socialization |
| Whaley et al., 2006 | Preschool | PAE children | Early adaptive deficits across all domains; Socialization deterioration pattern emerged in early childhood |
| Popova et al., 2023 | Children | FASD vs controls | FASD = significantly lower VABS scores vs controls |

Arrested Development in Adults

| Study | Age | Sample | Vineland Results |
|--------------------------|----------------------|------------------------------------|---|
| Streissguth et al., 1991 | Adolescents & Adults | FASD clinical cohort | Mean composite score = 7y (Socialization = 6y) |
| Streissguth et al., 1996 | Adolescents & adults | FASD cohort (N=415) | Mean composite score = 7y, arrested development in Socialization & Communication |
| Spohr et al., 2007 | Young Adults | FAS cohort followed from childhood | Persistent deficits into adulthood, especially in socialization & communication |
| Day et al., 2015 | Young Adults | Prospective PAE cohort vs controls | Mean adaptive composite lower in PAE |


DSM-5-TR: Arrested Development in ND-PAE

Development and Course

Among individuals with prenatal alcohol exposure, evidence of CNS dysfunction varies according to developmental stage. Although about one-half of young children prenatally exposed to alcohol show marked developmental delay in the first 3 years of life, other children affected by prenatal alcohol exposure may not exhibit signs of CNS dysfunction until they are preschool- or school-age. Additionally, impairments in higher order cognitive processes (i.e., executive functioning), which are often associated with prenatal alcohol exposure, may be more easily assessed in older children. When children reach school age, learning difficulties, impairment in executive function, and problems with integrative language functions usually emerge more clearly, and both social skills deficits and challenging behavior may become more evident. In particular, as school and other requirements become more complex, greater deficits are noted. Because of this, the school years represent the ages at which a diagnosis of ND-PAE would be most likely.

Functional Consequences

(assessing severity via the 'whole cloth' approach)




1996 CDC Secondary Disabilities Study

Diagnostic Analysis of Leroy Johnson: ND-PAE

| ND-PAE DIAGNOSTIC CRITERIA | LEROY JOHNSON | |
|--|---|---|
| Neurocognition (at least 1 impaired domain) | <u>Age 14</u> (Dr. Ohanesian): Academic Achievement Verbal Learning/Memory Auditory Processing | <u>Age 48</u> (Dr. Watson): Intellectual (IQ index discrepancies) Academic Achievement Verbal Learning/Memory Visuospatial Construction |
| Self-Regulation (at least 1 impaired domain) | <u>Age 14</u> and <u>Age 48</u> (Dr. Ohanesian & Dr. Watson): Executive Dysfunction: attention, mood, impulse control | |
| Adaptive Functioning (at least 2 impaired domains) | Communication Daily Living Skills Socialization | |
| Childhood Onset | Evidence: contemporaneous school records, witness statements | |
| Causes clinically significant distress in multiple contexts | All 8 Secondary Disabilities | |
| Differential Diagnosis | ND-PAE is the only condition that explains ALL lifelong functioning | |

ND-PAE: A cause-and-effect mental defect.




CAUSE:

Prenatal alcohol exposure directly causes brain damage that impairs executive (top-down) control over behavior.

EFFECT:

Brain damage in FASD explains lifelong adaptive impairment *in unstructured environments*.

Mr. Johnson's brain damage occurred through no fault of his own.
ND-PAE doesn't excuse his behavior, but it helps explain it.



Diagnosis:
Gateway to Forward-Thinking
Intervention

The Neuropsychological Assessment Battery

A proposed model standard for forensic assessment of Fetal Alcohol Spectrum Disorders

BY NATALIE NOVICK BROWN, PH.D.,
HON. ANTHONY P. WARTNIK, PAUL D. CONNOR, PH.D.,
AND RICHARD S. ADLER, M.D.

7 Domains of Neuropsychological Functioning

1. IQ (WAIS-IV)
2. Achievement (WRAT-4)
3. Learning and Memory (CVLT, RCFT)
4. Attention (CPT)
5. Motor Coordination (Grooved Pegs, Finger Tap)
6. Executive Functions (WCST, DKEFS, COWAT, RFF, Stroop, ACT, Trails)
7. Adaptive Functioning (VABS)



COMMENTARY

An Updated Fetal Alcohol Spectrum Disorder Assessment
Protocol for the Forensic Context

Natalie Novick Brown, Paul D. Connor, and Richard S. Adler
Department of Psychiatry, University of Washington

The 2026 Updated Protocol

Natalie Novick Brown *Editor*

Evaluating Fetal Alcohol Spectrum Disorders in the Forensic Context

A Manual for Mental Health Practice

Chapter 5 Neuropsychological Assessment of Fetal Alcohol Spectrum Disorder in Adults

Paul D. Connor

 Springer

Continues to Utilize the Nomenclature of IOM in Combination with the Structural Guidelines of the CDC

The Updated Protocol Utilizes 11 Domains

1. IQ (WAIS-IV)
2. Achievement (WRAT-4)
3. Visual Spatial Construction (e.g. RCFT)
4. Learning and Memory (CVLT, GSS2 Memory, RCFT)
5. Attention (CPT)
6. Motor Coordination (Grooved Pegs, Finger Tap)
7. Processing Speed (PSI, Trails A, Stroop)
8. Executive Functions (WCST, DKEFS, COWAT, RFF, Stroop, ACT, Trails) and Suggestibility (e.g. GSS2)
9. Communication
 1. Ability: NAB: AC
 2. Other Report: VABS Communication
10. Daily Living
 1. Ability: TFLS
 2. Other Report: VABS Daily Living
11. Socialization
 1. Ability: ACS: SC
 2. Other Report: VABS Socialization


Additional Analyses with the Updated Protocol

- Percentage of Scores within the Impaired Range
- Analysis of the “Functional Footprint”
- Comparison to Neuroimaging results
- Comparison with Other Justice Involved Individuals with FASD

Percentage of Scores within the Impaired Range

- Typically developing individuals can have ~10-15% of scores within the impaired range on a large battery of tests
- In FASD will expect larger percentage non-IQ scores to be within the impaired range:

Neuropsychological Testing of




Overall, 61.75% of non-IQ scores were within impaired range

- 36% mildly or mildly to moderately impaired range
- 19% moderately or moderately to severely impaired range
- 6.75% severely impaired range

The “Functional Footprint”


Neuropsychological Testing



- Variability of scores across the battery (and across domains of IQ)
- Academic impairment indicating Learning Disorders
- Impaired visuospatial perception or construction (RCFT Copy often the lowest score on neuropsychological testing)
- Disconnection between IQ and Adaptive Functioning
- Context-based performance (does more poorly on less structured and abstract tasks)

The “Functional Footprint”


Neuropsychological Testing



- Variability of scores across the battery (and across domains of IQ)
- Academic impairment indicating Learning Disorders
- Impaired visuospatial perception or construction (RCFT Copy often the lowest score on neuropsychological testing)
- Disconnection between IQ and Adaptive Functioning
- Context-based performance (does more poorly on less structured and abstract tasks)

The “Functional Footprint”


Neuropsychological Testing



- Variability of scores across the battery (and across domains of IQ)
- Academic impairment indicating Learning Disorders
- Impaired visuospatial perception or construction (RCFT Copy often the lowest score on neuropsychological testing)
- Disconnection between IQ and Adaptive Functioning
- Context-based performance (does more poorly on less structured and abstract tasks)

The “Functional Footprint”


Neuropsychological Testing



- Variability of scores across the battery (and across domains of IQ)
- Academic impairment indicating Learning Disorders
- Impaired visuospatial perception or construction (RCFT Copy often the lowest score on neuropsychological testing)
- Disconnection between IQ and Adaptive Functioning
- Context-based performance (does more poorly on less structured and abstract tasks)

The “Functional Footprint”

Neuropsychological Testing



- Variability of scores across the battery (and across domains of IQ)
- Academic impairment indicating Learning Disorders
- Impaired visuospatial perception or construction (RCFT Copy often the lowest score on neuropsychological testing)
- Disconnection between IQ and Adaptive Functioning
- Context-based performance (does more poorly on less structured and abstract tasks)

Comparison of Neuropsychological Findings with Neuroimaging


| Damaged Brain Regions per QEEG | Mr. X's Testing (z-scores) |
|---|---|
| <p>Left Temporal Lobes (auditory processing, short-term memory, receptive language, creation of new memories, retrieval of short-term memory, attention control)</p> | <p>CVLT List Learning Initial Learning = -0.3 Short Delay Memory = -1.5 Long Delay Memory = -1.5 WMS Story Immediate = -0.7 Delayed Memory = -0.7 GSS Story Learn = -1.3 Story Retention = -1.3 NAB Aud. Comprehension = 0.5</p> |
| <p>Occipital Lobes, especially the left (visual perception and spatial processing)</p> | <p>Trails A = -0.3 Stroop Color Naming = -1.3 Word Naming = -1.7 RFF Unique Designs = -1.1 BNT = -0.4 RCFT Figure Copy = -2.3 WAIS PSI = -1.3 WAIS PRI = -0.8</p> |

Comparison of Neuropsychological Findings with Neuroimaging


| Damaged Brain Regions per QEEG | Mr. X's Testing (z-scores) |
|--|---|
| <p>Parietal Lobes, especially the left (visual-spatial processing, short-term memory, executive attention, receptive language, awareness of emotional expression in others)</p> | <p>RCFT Figure Copy = -2.3 Trails A = -0.3 Trails B = -1.1 CVLT List Learning Initial Learning = -0.3 Short Delay Memory = -1.5 Long Delay Memory = -1.5 WMS Story Immediate = -0.7 Delayed Memory = -0.7 GSS Story Learn = -1.3 Story Retention = -1.3 NAB Aud. Comprehension = 0.5 WAIS WMI = -1.1 PRI = -1.3 WRAT Math Computation = -1.0 WJ Reading Comprehension = 0.3 CPT Reaction Time = -1.7 Standard Deviation = -1.7 ACS Social Perception = -1.0 Affect Naming = -1.0 Prosody = -0.7</p> |

Comparison with Other Justice Involved Individuals with FASD

Average Neuropsychological Profile of 131 Defendants Diagnosed with an FASD



Current and Prior Neuropsychological Testing Compared to Others with FASD n=131



MEDICAL ASSESSMENT

RICHARD S. ADLER, M.D.


**FORENSIC & CLINICAL PSYCHIATRY
THE PTSD INSTITUTE
SEATTLE, WA**

**CLINICAL FACULTY
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE**



OPINIONS

- **PFAS/ND-PAE = Brain damage at birth**
- **Traumatic Brain Injury**
- **FSIQ = 75**
- **Borderline Intellectual Functioning**
- **No exaggeration, no manipulation**
- **No Malingering, No Psychopathy**
- **Psychiatric illnesses pertinent to crime**



**DIAGNOSING
ND-PAE DOES NOT NEED
AN M.D. INVOLVED**

DIFFERENTIAL DIAGNOSIS GENETIC TESTING

**INTEGRATION WITH
NEUROPSYCHOLOGICAL
TESTING AND
NEUROIMAGING/
NEUROEVALUATIVE TESTING**

PHYSICAL EXAMINATION

FACIAL FEATURES
FAS FACIAL
PHOTOGRAPHIC ANALYSIS




FRONTAL VIEW
FAS FACIAL PHOTOGRAPHIC ANALYSIS

FAS Facial Photographic Analysis Report

| IDENTIFICATION | |
|-----------------|-----------------------------|
| Name | Steven Mulkey |
| First | Mulkey |
| Middle | Last |
| Subject I.D. | None |
| Source of Photo | RSA Psychiatric Examination |
| Gender | Male |
| Race | Caucasian/Caucasian |
| Birth Date | 10/6/1990 |

| PHOTO ASSESSMENT | | | |
|--|-------------------------|-------------------------|------------------------|
| Normal PFL Chart: | Caucasian (Hall '89) | | |
| Normal ICD Chart: | Caucasian (Hall '89) | | |
| Lip-Philtrum Guide: | Caucasian | | |
| Frontal | 3/4 View | Lateral | |
| File Name | Mulkey Frontal2 | | |
| Date of Photo | 3/29/2023 | | |
| Age (yrs) in photo | 32.48 | | |
| Date of Photo Assessment | 4/3/2023 | | |
| Photo Assessor | RSA | | |
| Length of Real Internal Measure of Scale (sticker) placed on forehead (mm) | | 19.05 | |
| Length of Internal Measure of Scale in Frontal Photo (pixels) | | 356.0 | |
| Left Palpebral Fissure Length: | In photo (pixels) 488.2 | True Length (mm) 28.7 | Z-score -1.65 |
| Right Palpebral Fissure Length: | In photo (pixels) 496.1 | True Length (mm) 29.2 | Z-score -1.24 |
| Mean Palpebral Fissure Length: | In photo (pixels) 492.2 | True Length (mm) 29.0 | Z-score -1.45 |
| Inner Canthal Distance (ICD): | In photo (pixels) 553.4 | True Distance (mm) 29.6 | Z-score -0.69 |
| Flat Philtrum (5-point rank): | In Frontal Photo 4 | In 3/4 Photo 4 | |
| Thin Upper Lip: Circularity (perimeter/area) | 55.5 | 5-Point rank (Circ) 2 | 5-Point rank (Scale) 2 |
| <input type="checkbox"/> down eyebrows <input type="checkbox"/> ptosis <input type="checkbox"/> strabismus <input type="checkbox"/> epicanthal folds <input type="checkbox"/> flat midface <input type="checkbox"/> protruding ears <input type="checkbox"/> flat nasal bridge <input type="checkbox"/> hypertelorism <input type="checkbox"/> | | | |
| Other anomalies present: <u>None reported</u> | | | |
| Comments: | | | |
| Other syndromes present: <u>None reported</u> | | | |

| PHOTO QUALITY | |
|--|--------------------------------|
| | Frontal 3/4 View Lateral |
| Side showing | |
| Head rotation (5-point rank/degree) to subject's Right (+) or Left (-) | |
| Head tilt (5-point rank) toward subject's Right (+) or Left (-) shoulder | |
| Head tilt (degrees) Up (+) or Down (-) from Frankfurt Horizontal Plane | |
| Exposure (3-point rank) | |
| Focus (3-point rank) | |
| Facial Expression (3-point rank) | |
| Reliability of ABC-Score for palpebral fissure length (5-point rank) | |
| Reliability of ABC-Score for philtrum (5-point rank) | |
| Reliability of ABC-Score for upper lip (5-point rank) | |

| OUTCOME | |
|--|--|
|  | ABC-Score B C A PFL Philtrum Lip Data Used mean 3/4 View circularity |
| No Picture Available No Picture Available | 4-Digit Diagnostic Code for Face 2: FAS features mild |
| Mulkey Frontal2 | |



Clinodactyly in Mr. Timothy Hurst

Hockey Stick Crease and Clinodactyly





Figure 6. Palmar side of the left hand
Curving of the 5th digit and a Hockey Stick Crease are present
Pg.15 of Dr. Adler's Report

Standard Height of Ears






Figure 2. Right facial profile


Upper red line shows the expected level of the external ear in line with the lateral margin of the eye. Lower line shows the level of Mr. Meade's right ear



Figure 3. Left facial profile

Upper red line shows the expected level of the external ear in line with the lateral margin of the eye. Lower line shows the level of Mr. Meade's left ear

CHAPTERS



1. Diagnostic History
2. Forensic Relevance (case law review)
3. Prevalence & Screening
4. Interviewing for PAE
5. Neuropsychological Assessment
6. Medical Assessment & Differential Diagnosis
- 7. NEUROIMAGING**
8. Functional/Adaptive Assessment
9. Comorbidity
10. Assessing Severity
11. Assessing Juveniles
12. Alternative Sentencing for Juveniles
13. Violence Risk Assessment in Prenatal Drug Exposure Cases
14. Sexually Violent Predator Civil Commitment Assessment
15. Competency Assessment
16. Pharmacotherapy
17. Prosecutorial Perspective (USA, Canada)
18. Views from the Bench (USA, Canada, New Zealand)

NEUROIMAGING:

BRAIN MRI

QUANTITATIVE BRAIN MRI

DTI

QUANTITATIVE DTI

QEEG

PET

**NEUROIMAGING
IS THE CHERRY ON TOP
NOT THE SUNDAE**



NEUROIMAGING:

**ILLUSTRATIVE EXHIBIT, NOT
NEEDED TO MAKE THE
DIAGNOSIS**


EVIDENTIARY ADMISSIBILITY


**CRUZ &
WALTON**

Table 10.3 Use and abuse of neuroimaging in the courtroom

1. Experts should present all relevant facts available in their testimony, ensure truthfulness and balance, and consider opposing points of view.
2. Experts should specify known deviations from standard practice.
3. Experts should have substantive knowledge and experience in the area in which they are testifying.
4. Experts should use standard terminology and describe standardization methods and the cohort characteristic from which claims are determined, when applicable.
5. Nonvalidated findings that are used to inform clinical pathology should be approached with great caution.
6. Recognized appropriateness guidelines should be used to assess whether the imaging technique used is appropriate for the particular question.
7. Experts should avoid drawing conclusions about specific behaviors based on the imaging data alone.
8. Experts should be willing to submit their testimony for peer review.
9. Experts should be prepared to provide a description of the nature of the neuroimages (e.g., representational/statistical maps when derived from computational postprocessing of several images) and how they were acquired.
10. Raw images and raw data should be made available for replication if requested.
11. Experts should be able to explain the reasoning behind their conclusions.
12. False positive rates should be known and considered if the expert's testimony includes quantitative imaging.
13. Experts should be prepared to discuss limitations of the technology and provide both confirming research and disconfirming studies.

Proposed Standards for Neuroradiology Imaging Testimony (From Meltzer et al., 2014, pg. 635)






NEUROCLOUD VOL

PatientID: 1818312
 Study: MR Brain w/o contrast 20/05/22
 Age: 32
 Id: 1744

Disclaimer


The results provided by Neurocloud VOL are not a diagnostic report but an image quantification tool. Qubitech Health Intelligence S.L. accepts no responsibility for the use of Neurocloud VOL for uses other than those specified.

Glass brain



Standard deviation 2 DS 2.5 DS 3.0 DS

| Parameter | Value |
|----------------------------------|--------------------------------------|
| TIV (Total Intracranial Volume) | 1,683.43 [cm3] |
| GM (Grey Matter) | 636.63 [cm3] |
| WM (White matter) | 694.57 [cm3] |
| CSF (Cerebrospinal fluid) | 349.23 [cm3] |
| BPF (Brain Parenchymal Fraction) | 79.25 (76.17 - 83.17) - [% (5 - 95)] |
| GMFPF (Grey Matter Fraction) | 38.00 (39.79 - 45.79) - [% (5 - 95)] |



NEURØCLOND VØL

PatientID: 1819312
Study: MR Brain wo contrast 20/05/22

ROIs analysis - Grey Matter


Standard deviation 2 DS 2.5 DS 3.0 DS

| ROI | Left hemisphere | | Right hemisphere | | Asymmetry [%] | Laterality |
|--|-----------------|-------------|------------------|-------------|---------------|------------|
| | GM [%TIV] | (5% - 95%) | GM [%TIV] | (5% - 95%) | | |
| Frontal | | | | | | |
| Precentral gyrus | 0.93 | 0.86 - 1.07 | 0.95 | 0.82 - 1.05 | -2.13 | |
| Superior frontal gyrus | 1.70 | 1.92 - 2.35 | 1.87 | 1.88 - 2.29 | -9.52 | Left |
| Middle frontal gyrus | 1.19 | 1.28 - 1.65 | 1.30 | 1.26 - 1.6 | -8.84 | Left |
| Inferior frontal gyrus Broca's area | 0.50 | 0.59 - 0.76 | 0.58 | 0.54 - 0.71 | -14.81 | Left |
| Cingulate gyrus, anterior part | 0.31 | 0.27 - 0.37 | 0.29 | 0.23 - 0.38 | 6.67 | |
| Anterior orbital gyrus | 0.74 | 0.7 - 0.85 | 0.83 | 0.76 - 0.95 | -11.46 | |
| Straight gyrus | 0.19 | 0.15 - 0.21 | 0.16 | 0.16 - 0.22 | 17.14 | Right |
| Temporal | | | | | | |
| Amygdala | 0.10 | 0.1 - 0.13 | 0.12 | 0.11 - 0.14 | -18.18 | Left |
| Hippocampus | 0.15 | 0.14 - 0.17 | 0.15 | 0.14 - 0.19 | 0.00 | |
| Parahippocampal gyrus | 0.21 | 0.18 - 0.25 | 0.21 | 0.19 - 0.25 | 0.00 | |
| Anterior temporal lobe, medial part | 0.31 | 0.3 - 0.4 | 0.34 | 0.3 - 0.38 | -9.23 | |
| Anterior temporal lobe, lateral part | 0.38 | 0.37 - 0.48 | 0.37 | 0.34 - 0.43 | 2.67 | |
| Temporal superior posterior part | 0.42 | 0.42 - 0.55 | 0.48 | 0.44 - 0.58 | -13.33 | |
| Middle and inferior temporal gyrus | 0.56 | 0.56 - 0.71 | 0.61 | 0.55 - 0.73 | -8.55 | |
| Posterior temporal lobe | 1.61 | 1.46 - 1.82 | 1.55 | 1.46 - 1.79 | 3.80 | |
| Fusiform gyrus | 0.20 | 0.17 - 0.23 | 0.21 | 0.17 - 0.23 | -4.88 | |
| Occipital | | | | | | |
| Lateral remainder of occipital lobe | 1.16 | 1.27 - 1.58 | 1.27 | 1.29 - 1.59 | -9.05 | |
| Cuneus | 0.30 | 0.3 - 0.42 | 0.28 | 0.29 - 0.41 | 6.90 | |
| Lingual gyrus | 0.39 | 0.41 - 0.62 | 0.40 | 0.4 - 0.59 | -2.53 | |
| Parietal | | | | | | |
| Postcentral gyrus | 0.78 | 0.74 - 0.93 | 0.77 | 0.68 - 0.91 | 1.29 | |
| Inferolateral remainder of parietal lobe | 1.07 | 1.12 - 1.42 | 1.14 | 1.15 - 1.42 | -6.33 | |
| Precuneus | 1.29 | 1.19 - 1.5 | 1.19 | 1.19 - 1.47 | 8.06 | |
| Cingulate gyrus, posterior part | 0.27 | 0.28 - 0.38 | 0.31 | 0.27 - 0.35 | -13.79 | Left |
| Internal structures | | | | | | |
| Insula | 0.55 | 0.5 - 0.62 | 0.46 | 0.48 - 0.63 | 17.82 | Right |
| Caudate nucleus | 0.19 | 0.2 - 0.28 | 0.22 | 0.2 - 0.27 | -14.63 | Left |
| Putamen | 0.21 | 0.22 - 0.32 | 0.15 | 0.23 - 0.32 | 33.33 | Bilateral |
| Thalamus | 0.24 | 0.24 - 0.42 | 0.27 | 0.25 - 0.41 | -11.76 | |
| Cerebellum | 2.29 | 2.54 - 3.21 | 2.17 | 2.44 - 3.14 | 5.38 | Bilateral |

NEURØCLØND VØL

PatientID: 1019312
Study: MR Brain wo contrast 20/05/22

ROIs analysis - SAGITTAL



Qubiotech Health Intelligence S.L.
(+34) 981 976 470 - help@qubiotech.com - www.qubiotech.com

Powered by
QUBIO tech

| | | | |
|-----------------------------------|----------------------------------|--|--|
| CNS Vital Signs Report | | Test Date: 2019 March 25 09:53:19 | |
| Patient ID: 600000100 | | Administrator: administrator | |
| Age: 40 | | Language: English (United States) | |
| Total Test Time: 53:35 (min:secs) | CNSVS Duration: 50:18 (min:secs) | Version 4.0.88 | |

| Patient Profile: | Percentile Range | | | | > 74 | 25 - 74 | 9 - 24 | 2 - 8 | < 2 |
|----------------------------|----------------------|----------------|------------|------|-------|----------|-------------|---------|----------|
| | Standard Score Range | | | | > 109 | 90 - 109 | 80 - 89 | 70 - 79 | < 70 |
| Domain Scores | Patient Score | Standard Score | Percentile | VI** | Above | Average | Low Average | Low | Very Low |
| Neurocognition Index (NCI) | | 75 | 5 | Yes | | | | x | |
| Composite Memory | 75 | 55 | 1 | Yes | | | | | x |
| Verbal Memory | 40 | 59 | 1 | Yes | | | | | x |
| Visual Memory | 35 | 67 | 1 | Yes | | | | | x |
| Psychomotor Speed | 175 | 102 | 55 | Yes | | x | | | |
| Reaction Time* | 881 | 59 | 1 | Yes | | | | | x |
| Complex Attention* | 11 | 88 | 21 | Yes | | | x | | |
| Cognitive Flexibility | 23 | 73 | 4 | Yes | | | | x | |
| Processing Speed | 43 | 83 | 13 | Yes | | | x | | |
| Executive Function | 26 | 76 | 5 | Yes | | | | x | |
| Social Cognition | 12 | 124 | 95 | Yes | x | | | | |
| Working Memory | 9 | 79 | 8 | No | | | | x | |
| Sustained Attention | 9 | 99 | 47 | Yes | | x | | | |
| Simple Attention | 22 | 87 | 19 | Yes | | | x | | |
| Motor Speed | 40 | 106 | 66 | Yes | | x | | | |
| | 132 | 116 | 86 | Yes | x | | | | |

Domain Dashboard: Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment. Reaction times are in milliseconds. An * denotes that "lower is better", otherwise higher scores are better. Subject Scores are raw scores calculations generated from data values of the individual subtests.

VI** - Validity Indicator: Denotes a guideline for representing the possibility of an invalid test or domain score. "No" means a clinician should evaluate whether or not the test subject understood the test, put forth their best effort, or has a clinical condition requiring further evaluation.

| Verbal Memory Test (VBM) | Score | Standard | Percentile | |
|----------------------------|-------|----------|------------|---|
| Correct Hits - Immediate | 8 | 67 | 1 | The VBM test measures how well a subject can recognize, remember, and retrieve words e.g. exploit or attend literal representations or attribute. Subjects have to remember 15 words and recognize them in a field of 15 distractors. There are two parts to this test, Immediate and Delayed. The delayed part is presented at the end of the battery. "Correct Hits" refers to the number of target words recognized. Low scores indicate verbal memory impairment. |
| Correct Passes - Immediate | 13 | 81 | 10 | |
| Correct Hits - Delay | 5 | 62 | 1 | |
| Correct Passes - Delay | 14 | 96 | 40 | |



QUANTITATIVE EEG (QEEG)

- Measures the different brain waves (e.g. alpha, beta, theta, and delta) at different sites looking at several parameters such as coherence and asymmetry. It then compares the results against a database of persons with “normal brains.”⁷⁰

BENEFITS OF QUANTITATIVE EEG (QEEG)

- 1. Convergent Validity**
- 2. Accusation(s) of malingering not applicable**
- 3. Localization**
- 4. Extent of abnormality**
- 5. Distribution pattern**
- 6. Networks involved**
- 7. Brain Optimization Index scores**
- 8. Correlation with performance testing/estimate of severity**
- 9. Correlation with pathophysiology/etiology of diagnosed disorder**
- 10. Remediable?**
- 11. Efforts to mitigate?**

Fig. 2- Example of Laplacian Absolute Power – eyes closed condition







Fig. 2- Example of Laplacian Absolute Power – eyes closed condition




Symptoms, Electrodes & Brodmann Areas






Example of swLORETA Coherence in the Frontal – Limbic Network in Theta (4 – 8 Hz)

[X = 0, Y = 30, Z = 20] mm - Brodmann Area: 24 - Left - Value = 2.65183 - Theta



© 2010-2014 Applied Neuroscience, Inc.



[X = 0, Y = 30, Z = 20] mm - Brodmann Area: 24 - Left - Value = 2.65183 - Theta




© 2010-2014 Applied Neuroscience, Inc.




Example of swLORETA Coherence in the Schizophrenia Network in Theta (4 – 8 Hz)



Example of swLORETA Predicted DTI of Information Flow in the Corpus Callosum in Theta (4-8 Hz)




Example of swLORETA Predicted DTI of Information Flow in the Corpus Callosum in Alpha (8-12 Hz)




Significant Z-Scores by Brain Lobe & Brodmann Areas

FRONTAL BRODMANN AREAS




TEMPORAL BRODMANN AREAS




■ LEFT ■ RIGHT

PARIETAL BRODMANN AREAS




OCCIPITAL BRODMANN AREAS




swLORETA Network Function Indices

Brain Optimization Index



Brain Network - Efficiency Levels




Mild Traumatic Brain Injury (mTBI) Discriminant Analysis

TBI DISCRIMINANT SCORE = -0.85

TBI PROBABILITY INDEX = 70.0%


The TBI Probability Index is the subject's probability of membership in the mild traumatic brain injury population. (see Thatcher et al, EEG and Clin. Neurophysiol., 73: 93-106, 1989.)



| | | | RAW | Z |
|--------|-----|-------|--------|-------|
| FP1-F2 | COH | Theta | 81.70 | -0.19 |
| T3-T5 | COH | Beta | 78.34 | 1.75 |
| C3-P3 | COH | Beta | 88.88 | 1.25 |
| FP2-F4 | PHA | Beta | -0.45 | -0.14 |
| F3-F4 | PHA | Beta | 0.55 | 0.29 |
| F4-T8 | AMP | Alpha | -3.88 | 0.51 |
| F8-T8 | AMP | Alpha | -74.22 | 0.08 |
| F4-T6 | AMP | Beta | 58.00 | 1.73 |
| F8-T6 | AMP | Beta | 9.13 | 1.71 |
| F3-O1 | AMP | Alpha | -41.48 | 0.48 |
| F4-O2 | AMP | Alpha | -51.07 | 0.27 |
| F7-O1 | AMP | Alpha | 102.07 | -0.14 |
| F4-O2 | AMP | Beta | 45.01 | 1.55 |
| P3 | RP | Alpha | 51.75 | -0.20 |
| P4 | RP | Alpha | 55.79 | -0.02 |
| O1 | RP | Alpha | 60.67 | 0.10 |
| O2 | RP | Alpha | 60.12 | 0.33 |
| T4 | RP | Alpha | 45.61 | 0.20 |
| T6 | RP | Alpha | 53.35 | -0.11 |
| T8 | RP | Alpha | 68.68 | 0.02 |

TBI SEVERITY INDEX = 5.43

This severity score places the patient in the MODERATE range of severity.



| | | | RAW | Z |
|---------|-----|-------|--------|-------|
| FP1-C3 | COH | Delta | 60.74 | 0.01 |
| FP1-FP2 | COH | Theta | 89.61 | 0.65 |
| O1-F7 | COH | Alpha | 11.27 | -1.30 |
| O2-T9 | COH | Alpha | 87.70 | 0.56 |
| P3-O1 | COH | Beta | 82.28 | 0.93 |
| FP1-T3 | PHA | Theta | -2.32 | -0.08 |
| T3-T4 | PHA | Theta | -3.69 | -0.73 |
| O1-F7 | PHA | Alpha | -19.44 | 0.51 |
| F7-F8 | PHA | Alpha | -1.71 | 0.01 |
| T6-T8 | PHA | Beta | 0.53 | -0.99 |
| C3-F7 | AMP | Delta | -25.55 | -3.12 |
| FP2-F4 | AMP | Delta | 40.54 | 1.14 |
| C4-F8 | AMP | Delta | 24.74 | -0.60 |
| O1-O2 | AMP | Theta | 4.18 | 0.19 |
| P3-F7 | AMP | Alpha | 81.78 | -0.42 |
| FP2-P4 | AMP | Alpha | -82.21 | -0.17 |

The TBI Severity Index is an estimate of the neurological severity of injury. (see Thatcher et al, J. Neuropsychiatry and Clinical Neuroscience, 13(1): 77-87, 2001.)

*Statement of Indications of Use:

The Discriminant Analysis and Severity Index are to be used by experienced and qualified professionals for the post-hoc statistical evaluation of the human electroencephalogram (EEG). The Discriminant Analysis and Severity Index are to be viewed as an adjunct to the evaluation of the patient, and they do not serve as a primary basis for a diagnosis. Warning: Inclusion criteria of a history of traumatic brain injury and greater than 13 years of age must be adhered to.

Comparison of Neuropsychological Findings with Neuroimaging: Skylar Meade

| Damaged Brain Regions per QEEG | Mr. Meade's Testing (z-scores) |
|---|--|
| <p>Frontal Lobes, especially the right (impulse control, executive functioning, abstract thinking, mood and social skills)</p> | <p>Finger Tapping (R) = -1.3 Finger Tapping (L) = -1.0 Grooved Pegs (R) = -0.6 Grooved Pegs (L) = -0.2 WRAT Word Reading = 0.0 WRAT Reading Comprehension = -0.93 COWAT Letters = 0.0 COWAT Category = -2.2 RFF Unique Designs = -1.0 Reynolds Interference Task = -3.73 Comprehensive Trails 5 = -1.3 ACT working memory = 0.48 to -2.27 TOGRA = -1.1 WCST Trials to First Category = -1.4 DKEFS Tower Total = -0.33 DKEFS Proverbs Accuracy = -1.67 GSS Total Suggestibility = -1.6 ACS Social Perception = 0.0 Affect Naming = -0.33 Prosody = 0.33</p> |


THE VALUE OF AN ONGOING DATABASE

| ITEM | MR. JASON THORNBURG | ORIGINAL COHORT (N= 19) MEAN SCORE (Standard Deviation) | CENTER UPDATED COHORT (N=12) MEAN SCORE (Standard Deviation) |
|-----------------------|---------------------|---|--|
| TBI Discriminant | | - 0.46 (1.27) | - 0.35 (1.01) |
| TBI Probability Index | | 71% (39) | 75% (36) |
| TBI Severity Index | | 2.63 (1.83) | 3.03 (2.10) |


| ITEM | MR. JASON THORNBURG | ORIGINAL COHORT (N= 19) MEAN SCORE (Standard Deviation) | CENTER UPDATED COHORT (N=12) MEAN SCORE (Standard Deviation) |
|-----------------------|---------------------|---|--|
| TBI Discriminant | - 0.85 | - 0.46 (1.27) | - 0.35 (1.01) |
| TBI Probability Index | 70% | 71% (39) | 75% (36) |
| TBI Severity Index | 5.43 | 2.63 (1.83) | 3.03 (2.10) |

DIFFUSION TENSOR IMAGING


CORPUS CALLOSUM TRACTOGRAPHY (DTI)




CORPUS CALLOSUM TRACTOGRAPHY (DTI)




Top 5 out of normative range bundles




As displayed in the image above, the top 5 out of normative range bundles in terms of microstructural measures are the **Anterior genu**, **Arcuate fasciculus left**, **Uncinate fasciculus right**, **Uncinate fasciculus left**, **Middle genu**. These bundles are situated as follow: 2 in the left hemisphere, 1 in the right hemisphere, 2 in the corpus callosum.



Whole white matter



| Measure | Percentile | Value | Normative range (mean (std)) |
|--|--------------|----------|------------------------------|
| ● Apparent diffusion coefficient ($10^{-6} \text{ mm}^2/\text{s}$) | 2.472 | 746.754 | 801.025 (27.622) |
| ● Fractional anisotropy | 93.169 | 0.36108 | 0.33798 (0.01552) |
| ● Axial diffusivity ($10^{-6} \text{ mm}^2/\text{s}$) | 5.627 | 1041.447 | 1099.159 (36.368) |
| ● Radial diffusivity ($10^{-6} \text{ mm}^2/\text{s}$) | 2.036 | 599.407 | 651.958 (25.680) |
| ● Volume (cm^3) | 3.488 | 709.269 | 824.874 (63.746) |




[Back to summary](#)

UDI: (010075401638711110)ANDN1.3.2
 ANDI is a regulated medical device in the USA.
 Click [here](#) to learn more.

[Go to glossary](#)
 imeka


POSITRON EMISSION TOMOGRAPHY



Glass brain

NEURONCLOUD PET

PatientID: 9912988378CTL
 Study: THORNBERG, Jason A 08271980
 Age: 44
 Id: 10551 Date: 2024-11-19 22:01:05



Glass brain

Hypometabolism

Standard deviation 2 SD 2.5 SD 3.0 SD

| Frontal | | | | |
|--|------------|-------------|----------|------------|
| ROI | Left Diff. | Right Diff. | Asymetry | Laterality |
| Precentral gyrus | 1.30 | 0.09 | 1.72 | |
| Superior frontal gyrus | 1.23 | 2.92 | 1.43 | |
| Middle frontal gyrus | 2.31 | 0.95 | 1.25 | |
| Inferior frontal gyrus (Broca area) | -0.61 | -0.74 | 0.77 | |
| Subgenual anterior cingulate gyrus | -4.38 | -6.56 | 7.00 | |
| Cingulate gyrus (gyrus cinguli), anterior part | -2.07 | -1.45 | 0.48 | |
| Anterior orbital gyrus | -3.63 | -3.77 | 0.23 | |
| Medial orbital gyrus | -6.08 | -3.30 | 2.12 | |
| Posterior orbital gyrus | -7.66 | -1.75 | 5.63 | |
| Lateral orbital gyrus | -5.43 | -8.55 | 4.46 | |
| Straight gyrus | -5.92 | -3.77 | 1.28 | |

| Temporal | | | | |
|--------------------------------------|------------|-------------|----------|------------|
| ROI | Left Diff. | Right Diff. | Asymetry | Laterality |
| Amigdala | -8.53 | -10.68 | 3.92 | |
| Hippocampus | -9.63 | -10.76 | 2.63 | |
| Parahippocampal and amient gyri | -11.58 | -14.31 | 3.72 | Bilateral |
| Anterior temporal lobe, medial part | -6.19 | -5.54 | 0.37 | |
| Anterior temporal lobe, lateral part | -0.31 | -1.71 | 0.69 | |
| Temporal Superior, Anterior Part | -3.22 | -6.42 | 2.89 | |
| Temporal Superior, Posterior Part | -0.36 | -3.24 | 3.78 | |
| Middle temporal and inferior | -4.99 | -6.99 | 0.92 | |
| Posterior temporal lobe | -2.16 | -1.46 | 0.59 | |
| Fusiform gyrus | -7.84 | -10.47 | 4.29 | |


| Parietal | | | | |
|---|------------|-------------|----------|------------|
| ROI | Left Diff. | Right Diff. | Asymetry | Laterality |
| Postcentral gyrus | 0.32 | -0.40 | 0.87 | |
| Inferiorlateral remainder of parietal lobe | -2.86 | -2.17 | 0.99 | |
| Precuneus | 1.84 | 1.27 | 1.83 | |
| Cingulate gyurs (gyrus cinguli), posterior part | 0.81 | -0.39 | 1.03 | |

| Occipital | | | | |
|-------------------------------------|------------|-------------|----------|------------|
| ROI | Left Diff. | Right Diff. | Asymetry | Laterality |
| Lateral remainder of occipital lobe | 9.55 | 8.40 | 1.18 | |
| Cuneus | 12.66 | 13.17 | 2.35 | |
| Lingual gyrus | 16.44 | 15.14 | 0.46 | |

| Internal structures | | | | |
|---------------------|------------|-------------|----------|------------|
| ROI | Left Diff. | Right Diff. | Asymetry | Laterality |
| Insula | -2.37 | -2.80 | 0.28 | |
| Caudate nucleus | -8.59 | -7.46 | 0.18 | |
| Putamen | -4.46 | -6.11 | 2.16 | |
| Thalamus | 1.60 | 1.70 | 1.49 | |
| Cerebellum | -1.04 | -2.33 | 1.13 | |

NEUROCLOND PET
PatientID: 9912988378CTL
Study: THORNBERG, Jason A 08271980

ROIs analysis - Hypermetabolism - SAGITTAL



In Press:


An Updated FASD Assessment Protocol for the Forensic Context

Natalie Novick Brown, Paul Connor, Richard S. Adler

ABSTRACT:

This article updates a recommended standard of practice for assessing fetal alcohol spectrum disorders (FASDs) in the forensic context. Initially published in 2010 to operationalize the forensic assessment process for FASD, this protocol has evolved in a continuous quality improvement (CQI) process that has incorporated relevant scientific developments with real-world forensic experience in hundreds of FASD cases around the United States, consistently meeting with general legal acceptance over the past 15 years. Based upon the same integrated multidisciplinary approach used in the clinical context to diagnose FASD disorders and **incorporating forward-thinking intervention (FTI) to improve post-evaluation adjustment and reduce risk of problematic behaviors**, the step-by-step process in this update is useful for both forensic mental health and legal professionals.

CHAPTERS



1. Diagnostic History
2. Forensic Relevance (case law review)
3. Prevalence & Screening
4. Interviewing for PAE
5. Neuropsychological Assessment
6. Medical Assessment & Differential Diagnosis
- 7. NEUROIMAGING**
8. Functional/Adaptive Assessment
9. Comorbidity
10. Assessing Severity
11. Assessing Juveniles
12. Alternative Sentencing for Juveniles
13. Violence Risk Assessment in Prenatal Drug Exposure Cases
14. Sexually Violent Predator Civil Commitment Assessment
15. Competency Assessment
- 16. PHARMACOTHERAPY**
17. Prosecutorial Perspective (USA, Canada)
18. Views from the Bench (USA, Canada, New Zealand)

RICHARD S. ADLER, M.D.

FORENSIC & CLINICAL PSYCHIATRY

1700 7th Avenue, Suite 210

Seattle, WA 98101

(206) 624 – 3800

www.fcpsych.com

richadler@fcpsych.com